Biosimilars Viable Only For Blockbuster Biologics?
This article was originally published in PharmAsia News
A report by economist Brill suggests that high development and compliance costs will limit the range of biosimilars that are developed. The study was funded by pharmacy benefit manager Prime Therapeutics.
You may also be interested in...
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.